Matthew L. Anderson, M.D., Ph.D.
Baylor College of Medicine
Obstetrics & Gynecology
One Baylor Plaza
MS: BCM 610
Houston, Texas 77030
Dr. Matthew Anderson uses high throughput screening strategies to identify novel therapeutic and diagnostic targets in ovarian cancer and uterine sarcomas. His laboratory particularly focuses on the role of microRNAs in gynecologic cancers. MicroRNAs are recently identified small, noncoding RNA transcripts that play a critical role in regulating diverse patterns of gene expression.
In collaboration with Drs. Martin Matzuk (BCM), Shannon Hawkins (BCM), Chad Creighton (BCM) and Preethi Gunaratne (University of Houston), Dr. Anderson has used high throughput sequencing strategies to comprehensively profile the microRNA transcriptome of ovarian cancers, fallopian tube, normal ovaries as well as healthy myometrium, leiomyomas and leiomyosarcomas. They have developed significant expertise in the application and analysis of the data generated by these strategies and, in doing so, identified more than 90 differentially expressed microRNAs implicated in the pathogenesis of female reproductive tract cancers. They are currently dissecting the roles of these microRNAs in regulating ovarian cancer growth and metastasis as well as the maintaining the pluripotency of ovarian cancer stem cells.
A vigorous area or research is the role of unique patterns of gene and microRNA expression in regulating the plasticity of uterine smooth muscle. Using bioinformatic algorithms, Dr. Anderson and his collaborators have identified hundreds of mRNA targets for each of the miRNAs potentially important for regulating the growth of ovarian and uterine tumors. They have also identified a number of novel miRNA transcripts unique to both ovarian and other gynecologic cancers as well as the female reproductive tract and defined a number of miRNA transcripts that appear to undergo extensive editing.
Lastly, Dr. Anderson is using the novel insights he and his team have generated to develop novel therapeutic strategies for treat ovarian cancers and uterine sarcomas using nano-shells and nanoparticles as tools for intracellular miRNA delivery and targeted combinatorial therapy. His work is currently supported by a program grant from the Ovarian Cancer Research Fund as well as grants from Young Texans Against Cancer and SLEH/Saks Fifth Avenue “Key to a Cure” Foundation.